Immuron Ltd (IMRN) Form 6-K — Oct 27, 2026
Immuron reported unaudited Q1 FY27 sales of AUD$2.2 million, up 9% year-over-year and 5% sequentially, driven by a successful Travelan brand re-launch in Australia. Australia led with AUD$1.8 million in sales (+14% YoY), where Travelan is growing at 26.4% versus category growth of 5.3%, and Canada surged 286% on brand awareness from Shoppers Drug Mart conference sampling.
Key figures
- Revenue
- AUD$2.2 million
- Revenue Yoy
- 9%
- Usa qoq
- -24%
- Usa yoy
- -19%
- Canada qoq
- 63%
- Canada yoy
- 286%
- Usa q1 sales
- AUD$0.3 million
- Australia qoq
- 12%
- Australia yoy
- 14%
- Q1 growth qoq
- 5%
- Canada q1 sales
- AUD$0.1 million
- Australia q1 sales
- AUD$1.8 million
- Travelan au growth vs category
- 26.4% vs 5.3% category growth
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.